What You Should Know:
– Capstan Medical, a medical technology company developing innovative solutions for heart valve disease secures $110M in a Series C funding round led by Eclipse with participation from existing investors Yu Galaxy and Intuitive Ventures, and new investment from Gideon Strategic Partners.
– Capstan Medical is developing a suite of next-generation heart valve implants and a first-of-its-kind catheter-based robotic delivery platform.
Addressing the Global Burden of Heart Valve Disease
Heart valve disease is a prevalent and serious condition affecting millions of people globally. Current treatment options, primarily open-heart surgery and catheter-based interventions, have limitations and are not suitable for all patients.
Capstan Medical is developing a minimally invasive solution that combines:
- Novel heart valve implants: Designed to improve valve function and durability.
- Advanced catheter technology: Enables precise and minimally invasive delivery of implants.
- Robotic platform: Enhances precision and control during the procedure.
This innovative approach aims to overcome the limitations of current treatments and expand access to effective heart valve repair and replacement for a broader range of patients.
Expanding Clinical and Development Efforts
Since its founding in 2020, Capstan Medical has assembled a team of experts in heart valve technology, implant delivery, and robotics. This new funding will enable the company to:
- Accelerate clinical trials: Conduct pivotal clinical trials to demonstrate the safety and efficacy of its technology.
- Expand research and development: Further refine and enhance its minimally invasive solutions.
- Scale operations: Prepare for commercialization and expand its reach to bring its technology to more patients.
“Percutaneous intervention has the opportunity to dramatically increase the treatment options for the millions of people suffering from heart valve disease. At Capstan, we believe that our robotic platform with a full portfolio of implants can uniquely address the urgent needs of this underserved patient population,” said Maggie Nixon, CEO of Capstan Medical. “We have pulled together the right people at the right time to make this happen and are energized by the incredible support of our investors.”
